• Pharmaceutical coverage and access in Parts A, B, C, and D. S. 2543, the Prescription Drug Pricing Reduction Act, H.R. 19, the Lower Costs, More Cures Act of 2019, and H.R. 3, the Lower Drug Costs Now Act.
• Advocacy regarding access to 340B reimbursement.
• Legislation amending the Patent Act, including reforms to patent eligible subject matter. S. 1416, the Affordable Prescriptions for Patients Act of 2019.

Duration: February 1, 2015 to December 31, 2019

General Issues: Medicare/Medicaid, Health Issues, Copyright/Patent/Trademark, Taxation/Internal Revenue Code

Spending: about $930,000 (But it's complicated. Here's why.)

It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.

Agencies lobbied since 2015: U.S. Senate, House of Representatives

Related Foreign Entities: Novartis AG (4056 Basel, SUI); contribution to lobbying: $0; ownership 100%